Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). The aim of the project is to develop and test in phase I small molecular chemicals, which will be candidates for drugs in the treatment of cancer such as non-small cell lung cancer and triple negative breast cancer. Compounds developed in a targeted and irreversible manner, unlike kinase inhibitors, will lead to selective and targeted by incorporation of a natural (blocked in tumour) process of ubiquitylation and degradation of a molecular target in cells. The new approach, unlike inhibition of protein activity, will result in a broad spectrum of cell changes, including mass induction of cancer cell death. So far, there is no information available on the development of similar molecules in the treatment of non-small cell lung cancer and triple negative breast cancer and therefore, the developed molecules will be the first-in-class approach. Cancer is one of the most common health problems in the world. In 2015 alone, nearly 9 million people died from cancer, where lung cancer was responsible for the highest number of deaths – 1.69 million people. The solutions available are ineffective and show serious side-effects – lung cancer is mainly based on resection, chemotherapy and radiotherapy, but their effectiveness is severely limited and the cancer recurrence is frequent. The result of the Project will have features and functionalities, which are currently not used in clinical practice, thus demonstrating a very high commercialisation potential.